2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs

C - Chemistry – Metallurgy – 07 – C

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07C 401/00 (2006.01) A61K 31/593 (2006.01) A61P 3/04 (2006.01) A61P 17/00 (2006.01) A61P 17/06 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) A61P 37/02 (2006.01)

Patent

CA 2730254

This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21 -dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1a,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti- cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has significant calcemic activity in vivo having about the same bone calcium mobilization activity and intestinal calcium transport activity as the native hormone 1.alpha.,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

Cette invention porte sur des analogues de la 2-méthylène-(17Z)-17(20)-déshydro-19,21 -dinor-vitamine D et, plus particulièrement, sur la 2-méthylène-(17Z)-17(20)-déshydro-19,21-dinor-1a,25-dihydroxyvitamine D3, et sur leurs utilisations pharmaceutiques. Ce composé présente une activité de transcription relativement élevée ainsi qu'une activité prononcée pour arrêter la prolifération de cellules non différenciées et pour induire leurs différenciations en monocyte démontrant ainsi une utilisation possible comme agent anti-cancéreux et pour le traitement de maladies de la peau, telles que le psoriasis ainsi que des états cutanés tels que les rides, la peau flasque, la peau sèche et une sécrétion insuffisante de sébum. Ce procédé a également une activité calcémique significative in vivo ayant à peu près la même activité de mobilisation du calcium de l'os et la même activité de transport intestinal que l'hormone native 1a,25-dihydroxyvitamine D3 et, par conséquent, peut être utilisée pour traiter des troubles auto-immuns ou des maladies inflammatoires chez les êtres humains ainsi que l'oestéodystrophie rénale. Ce composé peut également être utilisé pour le traitement ou la prévention de l'obésité.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2080059

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.